IFNG and neoplasm: First, the implementation of a “real-time monitoring–adaptive adjustment” strategy can be facilitated through dynamic biomarkers such as circulating tumor DNA (ctDNA) kinetics (56), the peripheral effector T cell to regulatory T cell ratio (57), and cytokine levels like IFN-γ (57).